Ⓐ
PeptiBrief
Peptide · Research peptide

BPC-157

Research peptide
Aliases · Body Protection Compound-157 · PL 14736 · Body protection compound 157

BPC-157 is an investigational peptide, analogue or research construct with evidence ranging from mechanistic studies to limited human trials.

Human
1/5
Animal
0/5
In-vitro
0/5
Safety
0/5
Last reviewed · 7/12/2026
Compare with another peptide →
Last reviewed7/12/2026
Evidence statusEvidence in progress
Published references2
Trust signal panel
Evidence & safety
  • Human evidence
    2/5
  • Animal evidence
    4/5
  • Mechanistic
    3/5
  • Safety knowledge
    2/5
  • Editorial confidence
    3/5
View in knowledge graph →See this peptide connected to conditions & mechanisms
01

Evidence Snapshot

Evidence snapshot · 2 verified refs
Overall
1/5Insufficient certainty
Human
1/5Only review or summary sources indexed (not counted as primary human evidence)
Animal
0/5None identified
In-vitro
0/5None identified
Safety
0/5None identified
02

Scientific identity

Molecular formula
C62H98N16O22
Molecular weight
1419.53 g/mol
Sequence
GEPPPGKPADDAGLV
Peptide family
Investigational peptide or analogue
Entity class
Research peptide
Alternative names
Body Protection Compound-157PL 14736Body protection compound 157
Discovery history

BPC-157 entered research or commercial use through work on its proposed biological, cosmetic or therapeutic activity.

02

Proposed Mechanisms

  • Angiogenesis promotion
    preclinical
  • Modulation of nitric-oxide (NO) system
    preclinical
  • Upregulation of growth factor receptors (e.g. VEGFR2)
    preclinical
  • Modulation of dopaminergic / serotonergic signalling
    hypothesised
  • Wound repair →
    supported
  • Angiogenesis →
    supported
  • Inflammation modulation →
    supported
03

Reported / Studied Uses

04

Human Evidence

Human evidence is absent, limited, early phase or indication-specific.

05

Animal Evidence

Animal evidence may support biological activity but does not establish clinical efficacy.

Species translation to humans is uncertain.
06

Safety & Unknowns

experimentalnot-licensedunlicensedlimited-human-datainvestigationallimited-human-evidenceno-established-general-use
Long-term safety, validated dosing and product quality may be uncertain outside formal clinical development.
07

Regulatory Status

CountryStatusNotes
United KingdomNot authorised as a medicineMay be treated as an unlicensed research chemical.
United StatesNot FDA-approvedPlaced on FDA Category 2 bulks list; compounding restricted.
European UnionNot authorisedNo EMA authorisation.
AustraliaProhibited without prescriptionSchedule 4/S0 under TGA depending on form.
08

Community Observations

Reports
2
% improved
100%
Avg before
3
Avg after
7
09

References

10

Full Disclaimer

This page is for educational information only. It does not constitute medical advice, diagnosis, treatment, dosing guidance, or a recommendation to use any peptide, medicine or research chemical. Many peptides discussed on Atlas are not approved for human use in most jurisdictions and may have limited or unknown long-term safety data.

Community observations shown on this page are anonymised, moderated and observational only. They do not establish safety or effectiveness.

Always consult a qualified healthcare professional before making decisions about your health. See medical disclaimer and methodology.

↳

Explore further

from the knowledge graph
Advertise here — support independent evidence →
ImportantPeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.